Literature DB >> 7826135

Urine neopterin: a new parameter for serial monitoring of disease activity in patients with systemic lupus erythematosus.

K L Lim1, K Muir, R J Powell.   

Abstract

OBJECTIVE: To investigate the role of serial measurement of urine neopterin concentration in monitoring the progression of systemic lupus erythematosus (SLE) disease activity scored using the British Isles Lupus Assessment Group (BILAG) index.
METHODS: We followed prospectively 68 unselected SLE patients for a total of 464 patient months during which 233 separate assessments were carried out. At each assessment, urine neopterin, determined by high performance liquid chromatography, together with erythrocyte sedimentation rate (ESR) and plasma C3, C4, and C3d were measured and the SLE disease activity scored by a single observer. Serial data sets were analysed using time series modelling techniques.
RESULTS: Single time point analysis showed a significant increase in urine neopterin concentrations in 14 patients who suffered flares of their disease during the study period (p = 0.02). Thirty patients with active disease went into disease remission with significant decreases in their urine neopterin values (p = 0.02). In the time series analysis, a statistically significant association was found between serial concentrations of urine neopterin and BILAG score (r = 0.6, p < 0.05); no other study parameter (ESR and serum C3, C4, and C3d) mirrored SLE disease activity as effectively.
CONCLUSIONS: This study provides initial evidence that changes in urine concentrations of neopterin are significantly correlated with fluctuations in disease activity over time, scored using the BILAG index, amongst individual patients with SLE. Consequently, serial urine neopterin measurements appear to be clinically useful for monitoring disease activity and may contribute substantially to therapeutic decision making in these patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7826135      PMCID: PMC1005455          DOI: 10.1136/ard.53.11.743

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  16 in total

Review 1.  Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application.

Authors:  H Wachter; D Fuchs; A Hausen; G Reibnegger; E R Werner
Journal:  Adv Clin Chem       Date:  1989       Impact factor: 5.394

2.  Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus.

Authors:  D D Gladman; C H Goldsmith; M B Urowitz; P Bacon; C Bombardier; D Isenberg; K Kalunian; M H Liang; P Maddison; O Nived
Journal:  J Rheumatol       Date:  1992-04       Impact factor: 4.666

3.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

Review 4.  Measurement of systemic lupus erythematosus activity in clinical research.

Authors:  M H Liang; S A Socher; W N Roberts; J M Esdaile
Journal:  Arthritis Rheum       Date:  1988-07

5.  Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG).

Authors:  D P Symmons; J S Coppock; P A Bacon; B Bresnihan; D A Isenberg; P Maddison; N McHugh; M L Snaith; A S Zoma
Journal:  Q J Med       Date:  1988-11

6.  Monitoring renal transplants: an application of the multiprocess Kalman filter.

Authors:  A F Smith; M West
Journal:  Biometrics       Date:  1983-12       Impact factor: 2.571

7.  Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants.

Authors:  C Huber; D Fuchs; A Hausen; R Margreiter; G Reibnegger; M Spielberger; H Wachter
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

8.  Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study.

Authors:  E J ter Borg; G Horst; E J Hummel; P C Limburg; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1990-05

9.  Liquid-chromatographic measurement of biopterin and neopterin in serum and urine.

Authors:  W E Slazyk; F W Spierto
Journal:  Clin Chem       Date:  1990-07       Impact factor: 8.327

10.  Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.

Authors:  C Huber; J R Batchelor; D Fuchs; A Hausen; A Lang; D Niederwieser; G Reibnegger; P Swetly; J Troppmair; H Wachter
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

View more
  3 in total

1.  Online pattern recognition in intensive care medicine.

Authors:  R Fried; U Gather; M Imhoff
Journal:  Proc AMIA Symp       Date:  2001

2.  Macrophage activation and coronary atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Young Hee Rho; Joseph Solus; Paolo Raggi; Annette Oeser; Tebeb Gebretsadik; Ayumi Shintani; C Michael Stein
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

Review 3.  Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review.

Authors:  Noémie Gensous; Aurélie Marti; Thomas Barnetche; Patrick Blanco; Estibaliz Lazaro; Julien Seneschal; Marie-Elise Truchetet; Pierre Duffau; Christophe Richez
Journal:  Arthritis Res Ther       Date:  2017-10-24       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.